Compare BGT & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGT | PROF |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.8M | 263.8M |
| IPO Year | 2004 | 2017 |
| Metric | BGT | PROF |
|---|---|---|
| Price | $10.89 | $7.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 130.3K | 115.0K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $10.22 | $3.92 |
| 52 Week High | $12.57 | $8.95 |
| Indicator | BGT | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 63.67 |
| Support Level | $10.83 | $6.47 |
| Resistance Level | $11.08 | $8.95 |
| Average True Range (ATR) | 0.12 | 0.48 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 69.23 | 70.13 |
Blackrock Floating Rate Income Trust is a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The company, as a secondary objective, also focuses on preservation of capital to the extent consistent with its primary objective of high current income. The Trust seeks to achieve its investment objectives by investing in worl-wide portfolio of floating rate securities, including investing a substantial amount in U.S. and non-U.S. senior secured floating rate loans (Senior Loans), made to corporate and other business entities.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.